Spots Global Cancer Trial Database for non muscle invasive bladder cancer
Every month we try and update this database with for non muscle invasive bladder cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer | NCT01697306 | Bladder Cancer | Gemcitabine 2 g BCG Vaccine | 18 Years - 85 Years | Azienda Ospedaliera San Giovanni Battista | |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | NCT00384891 | Urinary Bladder... Urinary Bladder... Urinary Bladder... Malignant Tumor... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Si... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | NCT04387461 | Non Muscle Inva... | CG0070 Pembrolizumab I... n-dodecyl-B-D-m... | 18 Years - | CG Oncology, Inc. | |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | NCT03914794 | Bladder Cancer NMIBC Non-Muscle Inva... Urothelial Carc... | Pemigatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC | NCT02895620 | Non Muscle Inva... Treatment by BC... | Xpert bladder T... | 18 Years - | Institut Claudius Regaud | |
| Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. | NCT06167356 | Non Muscle Inva... Non-Muscle Inva... Non-Muscle Inva... Bladder Cancer Bladder Disease Bladder Neoplas... Bladder Urothel... Bladder Cancer ... Bladder Cancer ... Bladder Urothel... Bladder Urothel... | 18 Years - | IRCCS San Raffaele | ||
| Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer | NCT06205277 | Bladder Cancer Non Muscle Inva... | Second TURBt | 18 Years - | University of Trieste | |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | NCT01498172 | Bladder Cancer | MAGE-A3 ASCI BCG | 18 Years - | University of Lausanne Hospitals | |
| Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | NCT03421236 | Non Muscle Inva... | Ty21a | 18 Years - | University of Lausanne Hospitals | |
| Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) | NCT05981131 | Non Muscle Inva... | N803 plus Bacil... | - | ImmunityBio, Inc. | |
| The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer | NCT01697306 | Bladder Cancer | Gemcitabine 2 g BCG Vaccine | 18 Years - 85 Years | Azienda Ospedaliera San Giovanni Battista | |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | NCT01498172 | Bladder Cancer | MAGE-A3 ASCI BCG | 18 Years - | University of Lausanne Hospitals | |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | NCT04819399 | Urinary Bladder... | Catumaxomab | 18 Years - | Lindis Biotech GmbH | |
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | NCT01799499 | Non Muscle Inva... | TC-3 hydrogel TC-3 hydrogel TC-3 hydrogel | 21 Years - | UroGen Pharma Ltd. | |
| Comprehensive Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Non Muscle-invasive Bladder Tumor; Can it Replace Second Look Biopsy? A Prospective Study | NCT03914001 | Bladder Cancer | mpMRI Second look TUR... | 18 Years - | Mansoura University | |
| Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging | NCT01004211 | Non Muscle Inva... | Narrow band ima... Standard transu... | 18 Years - | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer | NCT01731652 | Carcinoma in Si... Non Muscle Inva... | TMX-101 | 18 Years - | Telormedix SA | |
| Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer | NCT06205277 | Bladder Cancer Non Muscle Inva... | Second TURBt | 18 Years - | University of Trieste | |
| Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer | NCT06020807 | Non Muscle Inva... Non-Muscle Inva... | Bladder EpiChec... | 22 Years - | Nucleix Ltd. | |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | NCT02307487 | Bladder Cancer Neoplasms Urinary Bladder... Urologic Diseas... | 120 mg MMC in 9... 140 mg MMC in 9... 160 mg MMC in 9... 120 mg MMC in 6... 140 mg MMC in 6... 160 mg MMC in 6... | 18 Years - | UroGen Pharma Ltd. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients | NCT02891460 | Urinary Bladder... Urologic Neopla... Neoplasms Urinary Bladder... Urologic Diseas... | 40 mg MMC in 40... 80 mg MMC in 40... | 18 Years - | UroGen Pharma Ltd. | |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | NCT04387461 | Non Muscle Inva... | CG0070 Pembrolizumab I... n-dodecyl-B-D-m... | 18 Years - | CG Oncology, Inc. | |
| Comprehensive Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Non Muscle-invasive Bladder Tumor; Can it Replace Second Look Biopsy? A Prospective Study | NCT03914001 | Bladder Cancer | mpMRI Second look TUR... | 18 Years - | Mansoura University | |
| Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | NCT03421236 | Non Muscle Inva... | Ty21a | 18 Years - | University of Lausanne Hospitals | |
| A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer | NCT06181266 | NMIBC High Risk NMIBC Non Muscle Inva... | ZH9 | 18 Years - 99 Years | Prokarium Ltd | |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | NCT04819399 | Urinary Bladder... | Catumaxomab | 18 Years - | Lindis Biotech GmbH | |
| Comprehensive Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Non Muscle-invasive Bladder Tumor; Can it Replace Second Look Biopsy? A Prospective Study | NCT03914001 | Bladder Cancer | mpMRI Second look TUR... | 18 Years - | Mansoura University | |
| BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | NCT01498172 | Bladder Cancer | MAGE-A3 ASCI BCG | 18 Years - | University of Lausanne Hospitals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
